Description
Why It’s Done:
• To diagnose Non-Hodgkin Lymphoma (NHL): The IHC test helps confirm the presence of NHL and classifies it based on the CD markers expressed by the malignant lymphoid cells. NHL can be made up of both B-cell and T-cell lymphomas, and the markers help identify which type is present.
• To subtype lymphomas: NHL is a heterogeneous group of diseases, and identifying the specific subtype of lymphoma is important for prognosis and treatment planning. The IHC markers help distinguish between various types of B-cell lymphoma and T-cell lymphoma, aiding in choosing the right treatment approach.
• To monitor disease progression: This test can be used to determine whether lymphoma has spread or transformed, and to assess whether the disease is responding to treatment.
• To differentiate between other conditions: The test can help differentiate lymphoma from other conditions that might present with similar symptoms, such as infections or autoimmune diseases, by identifying the specific cellular markers.
• To predict prognosis: The pattern of CD marker expression can sometimes provide clues about the aggressiveness of the lymphoma and guide treatment decisions.
Preparation:
• Fasting: Fasting is typically not required for the IHC – NHL Immunophenotyping test.
• Tissue sample: The test requires a biopsy sample from affected tissue, typically a lymph node, bone marrow, or other sites affected by lymphoma. This biopsy can be collected via needle aspiration or surgical biopsy depending on the tumor location.
• Medications: It’s important to inform your healthcare provider about any medications, especially chemotherapy or immunosuppressive drugs, as these can affect the immune cells being analyzed.
• No special preparation: There are no dietary restrictions or lifestyle changes necessary before the test. However, follow any specific instructions from your healthcare provider regarding the biopsy procedure
